These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 15609005)

  • 61. Dendritic cells and cancer immunotherapy.
    Radford KJ; Tullett KM; Lahoud MH
    Curr Opin Immunol; 2014 Apr; 27():26-32. PubMed ID: 24513968
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dendritic cells in cancer immunotherapy.
    Vulink A; Radford KJ; Melief C; Hart DN
    Adv Cancer Res; 2008; 99():363-407. PubMed ID: 18037410
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents.
    Truxova I; Hensler M; Skapa P; Halaska MJ; Laco J; Ryska A; Spisek R; Fucikova J
    Int Rev Cell Mol Biol; 2017; 330():115-156. PubMed ID: 28215530
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Microenvironmental derived factors modulating dendritic cell function and vaccine efficacy: the effect of prostanoid receptor and nuclear receptor ligands.
    Raaijmakers TK; Ansems M
    Cancer Immunol Immunother; 2018 Nov; 67(11):1789-1796. PubMed ID: 29998375
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment.
    Saxena M; Bhardwaj N
    Trends Cancer; 2018 Feb; 4(2):119-137. PubMed ID: 29458962
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Dendritic cell vaccines loaded with autologous tumor lysates for solid tumors].
    Kamigaki T; Takahara M; Teruya T
    Nihon Rinsho; 2017 Feb; 75(2):288-294. PubMed ID: 30562866
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Engineering dendritic cells to enhance cancer immunotherapy.
    Boudreau JE; Bonehill A; Thielemans K; Wan Y
    Mol Ther; 2011 May; 19(5):841-53. PubMed ID: 21468005
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Strategies for improved antigen delivery into dendritic cells.
    Rea D; Johnson ME; Havenga MJ; Melief CJ; Offringa R
    Trends Mol Med; 2001 Mar; 7(3):91-4. PubMed ID: 11286763
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Dendritic cell-based vaccines: barriers and opportunities.
    Cintolo JA; Datta J; Mathew SJ; Czerniecki BJ
    Future Oncol; 2012 Oct; 8(10):1273-99. PubMed ID: 23130928
    [TBL] [Abstract][Full Text] [Related]  

  • 70.
    Castiello L; Aricò E; D'Agostino G; Santodonato L; Belardelli F
    Front Immunol; 2019; 10():2303. PubMed ID: 31611878
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Transendothelial migration (TEM) of in vitro generated dendritic cell vaccine in cancer immunotherapy.
    Ashraf MU; Jeong Y; Roh SE; Bae YS
    Arch Pharm Res; 2019 Jul; 42(7):582-590. PubMed ID: 30937843
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results.
    Mastelic-Gavillet B; Balint K; Boudousquie C; Gannon PO; Kandalaft LE
    Front Immunol; 2019; 10():766. PubMed ID: 31031762
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy.
    Qian D; Li J; Huang M; Cui Q; Liu X; Sun K
    Biomed Pharmacother; 2023 Jun; 162():114685. PubMed ID: 37058818
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Dendritic cell vaccines: A review of recent developments and their potential pediatric application.
    Elster JD; Krishnadas DK; Lucas KG
    Hum Vaccin Immunother; 2016 Sep; 12(9):2232-9. PubMed ID: 27245943
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Targeting adult and pediatric cancers via cell-based vaccines and the prospect of activated B lymphocytes as a novel modality.
    Coughlin CM; Vonderheide RH
    Cancer Biol Ther; 2003; 2(5):466-70. PubMed ID: 14614310
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis.
    Saadeldin MK; Abdel-Aziz AK; Abdellatif A
    Med Hypotheses; 2021 Jan; 146():110365. PubMed ID: 33221134
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A proposal for a simple and inexpensive therapeutic cancer vaccine.
    Fahrer AM
    Immunol Cell Biol; 2012 Mar; 90(3):310-3. PubMed ID: 21606943
    [TBL] [Abstract][Full Text] [Related]  

  • 78. New technologies toward dendritic cell-based cancer immunotherapies.
    Matsue H; Morita A; Matsue K; Takashima A
    J Dermatol; 1999 Nov; 26(11):757-63. PubMed ID: 10635619
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antigen delivery to plasmacytoid dendritic cells -induction of tolerance and immunity.
    Loschko J; Krug A
    Crit Rev Immunol; 2012; 32(6):489-501. PubMed ID: 23428225
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Regulatory dendritic cells: new targets for cancer immunotherapy.
    Shurin MR; Naiditch H; Zhong H; Shurin GV
    Cancer Biol Ther; 2011 Jun; 11(11):988-92. PubMed ID: 21474998
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.